Provided by Tiger Trade Technology Pte. Ltd.

Creative Medical Technology Holdings, Inc.

0.9346
-0.0306-3.17%
Post-market: 0.96320.0286+3.06%19:57 EDT
Volume:99.36K
Turnover:93.26K
Market Cap:7.10M
PE:-0.48
High:0.9800
Open:0.9300
Low:0.8820
Close:0.9652
52wk High:6.25
52wk Low:0.6200
Shares:7.59M
Float Shares:7.56M
Volume Ratio:0.37
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9543
EPS(LYR):-2.5200
ROE:-77.88%
ROA:-47.32%
PB:0.82
PE(LYR):-0.37

Loading ...

Creative Medical Technology - Holds 80% of Biodefense After Deal - SEC Filing

THOMSON REUTERS
·
Sep 26

Creative Medical Technology - Buys 4 Mln Biodefense Shares for $200,000 Cash and 1 Mln Shares on Sept 24 - SEC Filing

THOMSON REUTERS
·
Sep 26

Creative Medical Files New US Provisional Patent to Expand Ultrasome Cell-Free Platform Protection

Reuters
·
Sep 17

Creative Medical Technology - Files New U.S. Provisional Patent Application

THOMSON REUTERS
·
Sep 17

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

GlobeNewswire
·
Sep 17

Creative Medical Technology Holdings Stockholders Approved Increase in Authorized Common Shares to 100 Million

Reuters
·
Sep 01

Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’

TIPRANKS
·
Aug 21

Creative Medical Completes Enrollment, Treatment in FDA-Cleared ADAPT Trial of Olastrocel for Chronic Lower Back Pain

Reuters
·
Aug 20

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation and Phase 3 Planning

THOMSON REUTERS
·
Aug 20

Creative Medical Technology Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Creative Medical Net Loss Widens 22.5% to $1.51 Million in Q2 2026

Reuters
·
Aug 08

NASDAQ Trade Halt Volatility Trading Pause at 10:50 Am

Reuters
·
Aug 06

Creative Medical receives notice of allowance for new U.S. patent

TIPRANKS
·
Aug 06

Creative Medical Technology - Patent to Extend Ip Protection for Myelocelz Platform in Type 1 Diabetes

THOMSON REUTERS
·
Aug 06

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

GlobeNewswire
·
Aug 06

Top Premarket Gainers

MT Newswires Live
·
Aug 06

Creative Medical Technology Holdings Inc Expected to Post a Loss of 39 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Creative Medical Technology Holdings Issues Mid-year Update

THOMSON REUTERS
·
Jul 01

Creative Medical Technology Holdings Issues Mid-Year Update

GlobeNewswire
·
Jul 01

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

THOMSON REUTERS
·
Jul 01